JP2014523426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523426A5 JP2014523426A5 JP2014516405A JP2014516405A JP2014523426A5 JP 2014523426 A5 JP2014523426 A5 JP 2014523426A5 JP 2014516405 A JP2014516405 A JP 2014516405A JP 2014516405 A JP2014516405 A JP 2014516405A JP 2014523426 A5 JP2014523426 A5 JP 2014523426A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- pme
- medicament according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 7
- 102100037834 Protein phosphatase methylesterase 1 Human genes 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 108010086028 protein phosphatase methylesterase-1 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000030279 gene silencing Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101100030375 Dictyostelium discoideum pho2a gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 208000030224 brain astrocytoma Diseases 0.000 claims 1
- 208000024055 brain glioblastoma Diseases 0.000 claims 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims 1
- 201000007983 brain glioma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161499750P | 2011-06-22 | 2011-06-22 | |
| FI20115640 | 2011-06-22 | ||
| US61/499,750 | 2011-06-22 | ||
| FI20115640A FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Yhdistelmähoito |
| PCT/FI2012/050618 WO2012175798A2 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523426A JP2014523426A (ja) | 2014-09-11 |
| JP2014523426A5 true JP2014523426A5 (enExample) | 2015-07-30 |
| JP6001655B2 JP6001655B2 (ja) | 2016-10-05 |
Family
ID=44206849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516405A Expired - Fee Related JP6001655B2 (ja) | 2011-06-22 | 2012-06-15 | 併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9476050B2 (enExample) |
| EP (1) | EP2723450B1 (enExample) |
| JP (1) | JP6001655B2 (enExample) |
| CN (1) | CN103781514A (enExample) |
| CA (1) | CA2839807A1 (enExample) |
| DK (1) | DK2723450T3 (enExample) |
| FI (1) | FI20115640A0 (enExample) |
| WO (1) | WO2012175798A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10094834B2 (en) | 2012-08-30 | 2018-10-09 | Turun Yliopisto | Method of selecting individualized brain cancer therapy |
| US9663789B2 (en) * | 2013-04-26 | 2017-05-30 | Medical Diagnostic Laboratories, Llc | PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| AU2003290083A1 (en) | 2002-08-13 | 2004-03-11 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas |
| AU2003279004B2 (en) | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US20040077083A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| US20040077084A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| US20090182134A1 (en) * | 2002-11-14 | 2009-07-16 | Dharmacon, Inc. | siRNA targeting phosphatases |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2004096991A2 (en) * | 2003-04-25 | 2004-11-11 | Dana-Farber Cancer Institute, Inc. | Bcl2l12 polypeptide activators and inhibitors |
| US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| WO2005011598A2 (en) | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
| GB0612542D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
| US20090274682A1 (en) | 2008-02-05 | 2009-11-05 | The Trustees Of Princeton University | Demethylation and inactivation of protein phosphatase 2a |
| WO2010091140A1 (en) | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
-
2011
- 2011-06-22 FI FI20115640A patent/FI20115640A0/fi not_active Application Discontinuation
-
2012
- 2012-06-15 DK DK12767025.5T patent/DK2723450T3/en active
- 2012-06-15 EP EP12767025.5A patent/EP2723450B1/en not_active Not-in-force
- 2012-06-15 US US14/128,342 patent/US9476050B2/en not_active Expired - Fee Related
- 2012-06-15 CA CA2839807A patent/CA2839807A1/en not_active Abandoned
- 2012-06-15 CN CN201280040838.2A patent/CN103781514A/zh active Pending
- 2012-06-15 JP JP2014516405A patent/JP6001655B2/ja not_active Expired - Fee Related
- 2012-06-15 WO PCT/FI2012/050618 patent/WO2012175798A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102636384B1 (ko) | 스플라이싱을 조절하는 방법 및 조성물 | |
| DK2958907T3 (en) | Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders | |
| JP2014523426A5 (enExample) | ||
| CN105899493B (zh) | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 | |
| JP2014526456A5 (enExample) | ||
| Krützfeldt | Strategies to use microRNAs as therapeutic targets | |
| JP2011509949A5 (enExample) | ||
| JP2014526450A5 (enExample) | ||
| JP2015520143A5 (enExample) | ||
| WO2015092634A1 (en) | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders | |
| JP2016503799A5 (enExample) | ||
| JP2017061563A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| Seth et al. | RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer | |
| CN105899491A (zh) | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 | |
| JP2011006480A5 (enExample) | ||
| JP2014054250A5 (enExample) | ||
| MX385869B (es) | Agentes de iarn modificados. | |
| JP2012500197A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2015512254A (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| JP2013538213A5 (enExample) | ||
| JP2013544892A5 (enExample) |